Please Subscribe to get a daily link to Pat's blog via email


Your privacy is important to us. We will never spam you and keep your personal data secure.


25 02, 2013

Patient Snapshot: 21 year survivor, Jim Bond (Part One)

Tags: , , , , , |17 Comments

I first heard Jim Bond's myeloma story four years ago.  I met Jim and his wonderful wife, Kathleen, in Cambridge, Massachusetts.  We had volunteered to help Millennium Pharmaceuticals start a patient advisory board.  As we got to know each other in-between meetings, I learned that Jim was a sixteen year survivor, from Shaker Heights, Ohio,

21 12, 2012

If researchers can catch a break, many of us will live longer–a lot longer

Tags: , , , , , , |10 Comments

Significant news on the immunotherapy front.  A small bio-pharmaceutical company, Gliknik, put out a press release yesterday about their immunomodulator, post SCT study results that were presented at last week at ASH. Two things of note.  First, this is another University of Pennsylvania hosted study.  If you recall, Penn researchers administered the risky, yet highly

12 08, 2012

Millennium Pharmaceutical’s MLN9708 has a name: ixazomib

Tags: , , , |0 Comments

Remember this name: ixazomib (ix az' oh mib) Originally dubbed MLN9708, Millennium Pharmaceutical's experimental proteasome inhibitor has as much potential to help patients as any new anti-myeloma drug in the research pipeline. So don’t you think that it deserved a name? To clarify, this isn’t the new drug’s trade name. Think about Onyx’s new proteasome

27 07, 2012

Support group shout-out!

Tags: , |2 Comments

I never had a chance to thank the support group hosts from my trip to Los Angeles last weekend. Barbara Campbell, founder and leader of the El Segundo, California support group, was gracious and very knowledgeable.   We all sat in a circle and talked about our multiple myeloma experiences.  What a great group!  Only one

30 05, 2012

Why isn’t ASCO’s PR machine working overtime this week?

Tags: , , , , , , , , |0 Comments

I need to be honest with you.  I am underwhelmed by multiple myeloma related news coming out of Chicago this week ahead of the American Society of Oncology (ASCO) meetings Friday. Most years my inbox would be flooded with press releases, touting when and where results from any number of different myeloma related studies can

28 04, 2012

Velcade on the FDA’s Adverse Event list?

Tags: , , , , |0 Comments

I'll bet that no one else noticed this feature on Sokolove Law, LLC's website? FDA Watch List: Velcade 4/23/2012 Takeda Pharmaceuticals' Multiple myeloma medication Velcade (bortezomib) has found its way onto the Food and Drug Administration’s  “Adverse Event Reporting System” list for Q3 2011 because of a potential link between its usage and death when given

23 01, 2012

BREAKING NEWS: Velcade sub-q approved

Tags: , , |0 Comments

While it is a bit "after the fact," it is exciting to learn this evening that the FDA has approved administering Velcade sub-q. Let me share an email I received from company spokesperson, Peter Schrager, along with the official press release/announcement: Pat, Hope all is well. Today, Millennium: The Takeda Oncology Company announced that the

31 12, 2011

Millennium Pharmaceutical’s year in review

Tags: , , , , |0 Comments

I wanted to share some excerpts from a sort of "year in review" interview with Dr. Deborah Dunsire, CEO of Millennium Pharmaceuticals, makers of Velcade.  I found this article on a site called Mass High earlier this month: Millennium reports myeloma drug advances, updates drug recalls By Lori Valigra, Mass High Tech correspondent Cambridge: 

14 12, 2011

Great news for Velcade users who can’t stand needles…

Tags: , , , |4 Comments

Here is information about Millennium's new, oral proteasome inhibitor, MLN9708.  Looks like they are making good progress... Presentations at ASH Highlight results of Studies with MLN9708, First Oral Proteasome Inhibitorin Early Stage Clinical Trials in Multiple Myeloma CAMBRIDGE, Mass., Dec 13, 2011 Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited

13 12, 2011

Long awaited VISTA research data released at ASH

Tags: , , |2 Comments

Final results from the international, five year VISTA Velcade study were released yesterday at ASH.  Look this over and see what you think... Overall Survival Benefit with VELCADE® based Therapy in Previously Untreated Multiple Myeloma Patients Maintained after Five Year Follow-Up − VELCADE added to a standard frontline therapy demonstrates 43.9 percent overall survival improvement

2 12, 2011

What an amazing experience! (Part One)

Tags: , , , , , , , |11 Comments

Wednesday I took part in a media press event at the Charles Hotel in historic Cambridge, Massachusetts, located just across the river from Boston. Titled Surrogates or Survival: A Discussion on Endpoints in Multiple Myeloma Clinical Trials, the panel discussion  focused on the role of progression free survival (PFS) and overall survival (OS) data in

30 08, 2011

Now That I’m Feeling Better, I’m Available To Speak To Support Groups Anywhere In The U.S. Free Of Charge!

Tags: , , |0 Comments

I just received an email from a multiple myeloma support group member and regular reader, Karen, wondering if I could come speak to their group in South Carolina.  She even offered to let me stay in her home. GREAT NEWS!  I would love to travel to meet with any multiple myeloma support group, anywhere in

8 05, 2011

Early Results Show Velcade Is Also Effective As A Maintenance Therapy Agent, Post SCT

Tags: , , , , , , |2 Comments

If you have been following news from this week's International Myeloma Workshop in Paris, you couldn't help but notice how the big news centered around a Revlimid maintenance therapy.  The focus wasn't on how Revlimd maintenance extended progression free survival.  The excitement was generated by statistics which showed an 8% increase in patient median life expectancy.Here

31 03, 2011

Excellent Article About Geraldine Ferraro’s Legacy And Ongoing Battle To Help Control Cost Of Cancer Meds…

Tags: , , , , , , |1 Comment

Read this detailed recap/tribute to Geraldine Ferraro by Ann Law for Ferraro leaves cancer research, health reform legacyMarch 28th, 2011A symbol of progress for women in US politics, former Congresswoman Geraldine Ferraro died Saturday at the age of 75. Her death, caused by complications from blood cancer multiple myeloma, not only reminds the nation

23 03, 2011

Millennium Pharmaceuticls Launches 1000 CRANES OF HOPE Fundraising Campaign For IMF

Tags: , , |2 Comments

Millennium, makers of Velcade, have launched a fundraising campain for the International Myeloma Foundation (IMF), called 1000 CRANES OF HOPE.Here is some background information about the program:The promise of 1000 origami cranes.The ancient Japanese tradition of senbazuru promises that a person who folds 1000 cranes will be granted a wish, such as long life or recovery

19 03, 2011

Profile: Dr. Deborah Dunsire, Millennium Pharmaceuticals CEO

Tags: , , , |6 Comments

I have met Dr. Dunsire several times.  She is an incredibly impressive woman!  Tall, elegant, uber- intelligent--yet personable and approachable.I first met Dr. Dunsire at a reception for multiple myeloma patients who had agreed to volunteer to become members of a new patient advisory board Millennium Pharmaceuticals was starting two years ago.As she "worked the